• Ziopharm Oncology Inc., of New York, dosed its first patient in a Phase I trial of ZIO-201 (palifosfamide) with etoposide and cisplatin/carboplatin for small cell lung cancer. Palifosfamide is currently in Phase III for soft tissue sarcoma. The trial is being carried out at the Indiana University Cancer Center and will enroll 12 to 15 patients. It will evaluate safety of the combination drug regimen for a planned randomized Phase II trial.